ProfileGDS5678 / 1423348_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 26% 27% 27% 28% 27% 25% 26% 27% 27% 27% 27% 27% 27% 27% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6349426
GSM967853U87-EV human glioblastoma xenograft - Control 22.6232527
GSM967854U87-EV human glioblastoma xenograft - Control 32.6245927
GSM967855U87-EV human glioblastoma xenograft - Control 42.5864828
GSM967856U87-EV human glioblastoma xenograft - Control 52.5835527
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6454625
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6312726
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6026127
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5907927
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.610627
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6041727
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5973127
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6127827
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6090927